Engine Capital Management’s Trinity Biotech TRIB Stock Holding History

Engine Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-859	Closed	-$12K	–	56
2019 Q1	$12K	Hold	859	–	–	0.01%	48
2018 Q4	$10K	Hold	859	–	–	0.01%	48
2018 Q3	$17K	Hold	859	–	–	0.02%	48
2018 Q2	$21K	Hold	859	–	–	0.01%	52
2018 Q1	$22K	Hold	859	–	–	0.01%	45
2017 Q4	$22K	Buy	+859	New	+$22.1K	0.01%	35

Other funds holding TRIB

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

ARM

Adirondack Research & Management Guilderland, New York $82.2M AUM 63.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Engine Capital Management's TRIB Position: Q2 2019 in Review

Engine Capital Management sold out of Trinity Biotech (TRIB) in Q2 2019, closing a stake of 859 shares — an estimated $12K sold.

Engine Capital Management first reported a position in TRIB in Q4 2017 and held it in 6 quarters. The position peaked at $22K in Q1 2018. 35 funds tracked by Wall St. Rank hold TRIB as of Q2 2019.

Engine Capital Management reported no remaining Trinity Biotech position as of Q2 2019 after selling out during the quarter.
Engine Capital Management sold 859 Trinity Biotech shares in Q2 2019, an estimated $12K.
Engine Capital Management first reported a position in Trinity Biotech in Q4 2017 and held it in 6 quarters.
Engine Capital Management's Trinity Biotech position peaked at $22K in Q1 2018.
35 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2019.

Based on Engine Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.